Biological drugs are less toxic to the body and more effective than traditional therapies. This review describes new psoriasis treatments, which are on the market or currently in clinical trials that are being used to treat moderate-to-severe plaque psoriasis. Thus, it has been shown that some cytokines such as IL-8 cause the accumulation of neutrophils in the skin 15. These treatments are used for severe cases and are used as a last resort because they have a high cost and significant side effects. Largely unchanged for decades, treatment methods for this potentially disabling condition are finally evolving. The management of psoriasis has remained largely unchanged for decades. Figure 9: Psoriatic nail involvementmay be seen in isolation. Past president GPMA. Although the last decade has seen a number of paradigm changes in the therapeutic options for PsA, response to treatment is highly variable. 10, with therefore promising potential for use as predictive biomarkers. A limited number of pharmacogenetic studies to predict TNFi treatment response have been conducted to date specifically in PsA. Non-biologic Disease-Modifying Anti-rheumatic Drugs.
However, over the past decade, a large amount of evidence has defined a role for the immune system and its interactive network of leukocytes and cytokines in disease pathogenesis. In turn, recent data from clinical trials using immune-modifying drugs (Tables 1 and and2)2) have further informed the research community about the involvement of specific immune-cell types and cytokines in disease pathology. The first clear evidence that T cells contributed to the epidermal abnormalities seen in psoriasis was demonstrated by treatment with the fusion toxin DAB389IL-2, a protein that induces apoptosis of cells expressing functional IL-2 receptors and thus is a highly selective antagonist of activated T cells. Biologic therapies have provided a clear advance in the treatment of rheumatological conditions. Initial trial results with new agents are promising, and, in time, head-to-head trials will establish the best treatment options for patients. Although non-biological therapies, including methotrexate and ciclosporin, show significant efficacy their side effect profiles have precluded their long term use for moderate to severe psoriasis. In psoriasis, these agents are designed to specifically interfere with T cell activation and effector functions. Several anti-TNF drugs have been used successfully to treat psoriasis and PsA. Research in the past decade has brought much progress in the understanding of the immunopathogenesis and genetics of psoriasis, leading to the development of more targeted therapies.
Putting Together The Psoriasis Puzzle: An Update On Developing Targeted Therapies